Abstract. We describe a case of post-kala-azar dermal leishmaniasis occurring after diagnosis of visceral leishma-niasis in an HIV-1–infected woman. The skin lesions did not recover after treatment with oral miltefosine at 100 mg/day for five cycles of 28 days but responded to treatment with liposomal amphotericin B
Leishmaniasis is emerging as a common and serious opportunistic disease for patients with HIV infect...
Post-kala-azar dermal leishmaniasis (PKDL) is very uncommon among HIV-positive patients, and very fe...
Current treatment options for visceral leishmaniasis (kala-azar) are pentavalent antimony, amphoter...
The first two patients to be treated with miltefosine for post-kala-azar dermal leishmaniasis (PKDL)...
We report a case of post-kala-azar dermal leishmaniasis (PKDL) in a woman with AIDS which occurred 1...
Post-kala-azar dermal leishmaniasis (PKDL) is a complication of visceral leishmaniasis (VL) observed...
Post-kala-azar dermal leishmaniasis (PKDL) is a neglected tropical disease characterized by a dermat...
We describe here a case of disseminated cutaneous leish-maniasis due to Leishmania major in a severe...
Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, p...
Background: Coinfection with HIV and Leishmania represents a major health problem worldwide. Recent ...
Post-kala-azar dermal leishmaniasis (PKDL) is clinical outcome of visceral leishmaniasis (VL) and is...
Abstract Background Post-kala-azar dermal leishmaniasis (PKDL) is a dermatosis that occurs 2–3 years...
Post-kala-azar dermal leishmaniasis (PKDL) is rarely reported in South America. In spite of the fact...
Leishmaniasis is emerging as a common and serious opportunistic disease for patients with HIV infect...
Post-kala-azar dermal leishmaniasis (PKDL) is rarely reported in South America. In spite of the fact...
Leishmaniasis is emerging as a common and serious opportunistic disease for patients with HIV infect...
Post-kala-azar dermal leishmaniasis (PKDL) is very uncommon among HIV-positive patients, and very fe...
Current treatment options for visceral leishmaniasis (kala-azar) are pentavalent antimony, amphoter...
The first two patients to be treated with miltefosine for post-kala-azar dermal leishmaniasis (PKDL)...
We report a case of post-kala-azar dermal leishmaniasis (PKDL) in a woman with AIDS which occurred 1...
Post-kala-azar dermal leishmaniasis (PKDL) is a complication of visceral leishmaniasis (VL) observed...
Post-kala-azar dermal leishmaniasis (PKDL) is a neglected tropical disease characterized by a dermat...
We describe here a case of disseminated cutaneous leish-maniasis due to Leishmania major in a severe...
Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, p...
Background: Coinfection with HIV and Leishmania represents a major health problem worldwide. Recent ...
Post-kala-azar dermal leishmaniasis (PKDL) is clinical outcome of visceral leishmaniasis (VL) and is...
Abstract Background Post-kala-azar dermal leishmaniasis (PKDL) is a dermatosis that occurs 2–3 years...
Post-kala-azar dermal leishmaniasis (PKDL) is rarely reported in South America. In spite of the fact...
Leishmaniasis is emerging as a common and serious opportunistic disease for patients with HIV infect...
Post-kala-azar dermal leishmaniasis (PKDL) is rarely reported in South America. In spite of the fact...
Leishmaniasis is emerging as a common and serious opportunistic disease for patients with HIV infect...
Post-kala-azar dermal leishmaniasis (PKDL) is very uncommon among HIV-positive patients, and very fe...
Current treatment options for visceral leishmaniasis (kala-azar) are pentavalent antimony, amphoter...